FGFR3 and urothelial carcinoma: In the phase II BLC2001 trial, erdafitinib brought an ORR of 40% to patients with urothelial carcinoma susceptible to FGFR3 or FGFR2 genetic alterations whose diseases progressed during or following at least one line of prior platinum‐containing chemotherapy.